<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014104</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Emb-005</org_study_id>
    <nct_id>NCT01014104</nct_id>
  </id_info>
  <brief_title>Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome</brief_title>
  <official_title>Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation Syndrome in In-vitro Fertilization Cycles: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomized clinical controlled trial to assess the efficacy of&#xD;
      the Methylprednisolone for preventing ovarian hyper stimulation syndrome in in vitro&#xD;
      fertilization (IVF) cycles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian hyper stimulation syndrome is the most serious complication of ovarian stimulation&#xD;
      which might be life threatening in the severe forms. Since there is still no definite cure&#xD;
      for this syndrome, prevention is considered as an essential and vital issue. The objective of&#xD;
      this study is to determine the effect of Methylprednisolone to prevent ovarian hyper&#xD;
      stimulation syndrome in IVF cycles.&#xD;
&#xD;
      The study population comprises all infertile patients with diagnosis of polycystic ovarian&#xD;
      syndrome which will undergo of in-vitro fertilization. The PCO subjects will be recognized&#xD;
      based on the Rotterdam criteria inclusive the presence of least 2 signs of oligomenorrhea,&#xD;
      hyper androgynism (clinical or laboratory), LH/FSH&gt;2 and ovarian morphological evidences in&#xD;
      Doppler ultrasound.&#xD;
&#xD;
      The existence of more than 20 follicles in both ovaries and E2 concentration &gt;4000 pg/ml will&#xD;
      be considered as the OHSS risk factors.&#xD;
&#xD;
      In this study all eligible patients will be randomly allocated into two study groups by a&#xD;
      computerized randomization method:&#xD;
&#xD;
      Treatment group (case) will be administered 16 mg Methylprednisolone initiated from the first&#xD;
      day of stimulation and will be tapered after the first pregnancy test (day 13 after the&#xD;
      embryo transfer). Furthermore, these patients will receive a bolus IV dose&#xD;
      methylprednisolone, 1g on the day of egg collection and embryo transfer.&#xD;
&#xD;
      Patients in the control group will not receive any treatment with glucocorticoids. If each&#xD;
      group confronts with every kind of high risk signs or symptoms, they will undergo coasting or&#xD;
      gonadotropin withdrawal or other treatment strategies.&#xD;
&#xD;
      The presence of OHSS is defined in accordance with the Golan 5 grade system and women who at&#xD;
      least are at grade 2 of this classification (Mild) considered as OHSS cases and will&#xD;
      experience abdominal distention and discomfort, nausea and vomiting and/or diarrhea and&#xD;
      enlargement of ovaries(5-12cm). In Moderate forms, ultrasound evidences of ascites will be&#xD;
      observed and severe OHSS accompany with clinical signs of ascites, hydrothorax, breathing&#xD;
      disorders, hemoconcentration, coagulopathy and renal perfusion decrease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence rate of Ovarian hyper stimulation syndrome</measure>
    <time_frame>Until 20 days after embryos transfer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estradiol concentration in the day before hCG administration</measure>
    <time_frame>Until 20 days after embryos transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrieved and injected oocytes number and quality</measure>
    <time_frame>Until 20 days after embryos transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieved and transferred embryos number and quality</measure>
    <time_frame>Until 20 days after embryos transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>Until 20 days after embryos transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemical and clinical pregnancy rate and cancelation rate</measure>
    <time_frame>Until 20 days after embryos transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Methylprednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Administration of Methylprednisolone</description>
    <arm_group_label>Case</arm_group_label>
    <other_name>Case</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Normal salin injection</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Poly Cystic Ovarian Syndrome patients&#xD;
&#xD;
          -  Indication for IVF/ICSI and Long Protocol ovarian stimulation&#xD;
&#xD;
          -  Basal FSHâ‰¥10&#xD;
&#xD;
          -  Normal BMI (20-25)&#xD;
&#xD;
          -  physical health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to GnRH analogues, FSH and corticosteroids&#xD;
&#xD;
          -  presence of heart failure, recent myocardial infarction&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  hypothyroidism&#xD;
&#xD;
          -  hepatic failure&#xD;
&#xD;
          -  osteoporosis&#xD;
&#xD;
          -  peptic ulceration&#xD;
&#xD;
          -  renal impairment&#xD;
&#xD;
          -  Using drugs that have interaction with corticosteroids such&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashraf Moini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology and Female Infertility Department, Reproductive Medicine Research Center, Royan institute, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marzieh Shiva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology and Female Infertility Department, Reproductive Medicine Research Center, Royan institute, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Narges bagheri lankarani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology and Female Infertility Department, Reproductive Medicine Research Center, Royan institute, ACECR, Tehran, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <zip>14114</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.royaninstitute.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 13, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>July 14, 2011</last_update_submitted>
  <last_update_submitted_qc>July 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hamid Gourabi, Chief</name_title>
    <organization>Royan Institute</organization>
  </responsible_party>
  <keyword>Ovarian hyper stimulation syndrome</keyword>
  <keyword>Methylprednisolone</keyword>
  <keyword>IVF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

